JP2025502442A5 - - Google Patents
Info
- Publication number
- JP2025502442A5 JP2025502442A5 JP2024543244A JP2024543244A JP2025502442A5 JP 2025502442 A5 JP2025502442 A5 JP 2025502442A5 JP 2024543244 A JP2024543244 A JP 2024543244A JP 2024543244 A JP2024543244 A JP 2024543244A JP 2025502442 A5 JP2025502442 A5 JP 2025502442A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- gepotidacin
- vancomycin
- infections
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263301522P | 2022-01-21 | 2022-01-21 | |
| US63/301,522 | 2022-01-21 | ||
| PCT/EP2023/051177 WO2023139147A1 (en) | 2022-01-21 | 2023-01-19 | Gepotidacin and vancomycin for use in the treatment of an infection caused by staphylococcus saprophyticus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025502442A JP2025502442A (ja) | 2025-01-24 |
| JP2025502442A5 true JP2025502442A5 (https=) | 2026-01-22 |
Family
ID=85108785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024543244A Pending JP2025502442A (ja) | 2022-01-21 | 2023-01-19 | Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ｓａｐｒｏｐｈｙｔｉｃｕｓによって引き起こされる感染症の処置における使用のためのゲポチダシンおよびバンコマイシン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250099535A1 (https=) |
| EP (1) | EP4465989A1 (https=) |
| JP (1) | JP2025502442A (https=) |
| CN (1) | CN118574619A (https=) |
| CA (1) | CA3240991A1 (https=) |
| WO (1) | WO2023139147A1 (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008240764C1 (en) | 2007-04-20 | 2011-10-20 | Glaxo Group Limited | Tricyclic nitrogen containing compounds as antibacterial agents |
| EP3946342A1 (en) * | 2019-04-03 | 2022-02-09 | GlaxoSmithKline Intellectual Property Development Limited | Gepotidacin for use in the treatment of bacterial urinary tract infections |
-
2023
- 2023-01-19 JP JP2024543244A patent/JP2025502442A/ja active Pending
- 2023-01-19 CA CA3240991A patent/CA3240991A1/en active Pending
- 2023-01-19 CN CN202380017824.7A patent/CN118574619A/zh active Pending
- 2023-01-19 EP EP23702056.5A patent/EP4465989A1/en active Pending
- 2023-01-19 US US18/728,991 patent/US20250099535A1/en active Pending
- 2023-01-19 WO PCT/EP2023/051177 patent/WO2023139147A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018357775B2 (en) | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD) | |
| JP2018513188A5 (https=) | ||
| JP2023541432A5 (https=) | ||
| JP2023541430A5 (https=) | ||
| JP2012082219A (ja) | 感染症の治療 | |
| AU2019328903B2 (en) | Composition for eradicating Helicobacter pylori | |
| JP2015537009A5 (https=) | ||
| CN115279781A (zh) | 抗体药物偶联物及其医药用途 | |
| CN111939156B (zh) | 一种联合抗菌药物组合物及其应用 | |
| JP2019533660A5 (https=) | ||
| JP2020529995A5 (https=) | ||
| JP2018531273A5 (https=) | ||
| JP2022551691A5 (https=) | ||
| JP2023545372A5 (https=) | ||
| JP2020536048A5 (https=) | ||
| JP2022539583A5 (https=) | ||
| JP2025502064A5 (https=) | ||
| JP2025502442A5 (https=) | ||
| CN107714678B (zh) | 紫檀芪在制备mcr-1酶抑制剂中的应用 | |
| JP2021512086A5 (https=) | ||
| JP5854987B2 (ja) | 感染症治療用のチオキサンテン誘導体 | |
| JP2023516753A5 (https=) | ||
| CN115607545B (zh) | 依达拉奉在自闭症谱系障碍治疗中的应用 | |
| JP2023518430A5 (https=) | ||
| JP2015524460A5 (https=) |